These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1686817)

  • 41. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
    Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
    Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
    Bastani B; Nash JF; Meltzer HY
    Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of the selective serotonin reuptake inhibitor fluoxetine in temperature regulation in ovariectomized rat models.
    Maswood N; Cosmi S; Alfinito PD; Leventhal L; Deecher DC
    Neuroendocrinology; 2006; 84(5):330-8. PubMed ID: 17192701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-HT(1A) receptor dysfunction in female patients with schizophrenia.
    Lee MA; Meltzer HY
    Biol Psychiatry; 2001 Nov; 50(10):758-66. PubMed ID: 11720694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroendocrine effects of azapirones.
    Cowen PJ; Anderson IM; Grahame-Smith DG
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):21S-25S. PubMed ID: 1973937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.
    Levy AD; Li Q; Van de Kar LD
    Neuropharmacology; 1994; 33(3-4):335-42. PubMed ID: 7984271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation.
    Ho EV; Thompson SL; Katzka WR; Sharifi MF; Knowles JA; Dulawa SC
    Psychopharmacology (Berl); 2016 Jan; 233(1):57-70. PubMed ID: 26423528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
    Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
    Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obsessive-compulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents.
    Murphy DL; Pato MT; Pigott TA
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):91S-100S. PubMed ID: 1973944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 5-HT1A receptor function in depression: effect of chronic amitriptyline treatment.
    Lesch KP; Disselkamp-Tietze J; Schmidtke A
    J Neural Transm Gen Sect; 1990; 80(2):157-61. PubMed ID: 2317317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
    Markovitz PJ; Stagno SJ; Calabrese JR
    Am J Psychiatry; 1990 Jun; 147(6):798-800. PubMed ID: 2188516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-HT1A-sensitive adenylyl cyclase of rodent hippocampal neurons: effects of antidepressant treatments and chronic stimulation with agonists.
    Varrault A; Leviel V; Bockaert J
    J Pharmacol Exp Ther; 1991 Apr; 257(1):433-8. PubMed ID: 2020001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of hydrocortisone on brain 5-HT function and sleep.
    Young AH; Sharpley AL; Campling GM; Hockney RA; Cowen PJ
    J Affect Disord; 1994 Oct; 32(2):139-46. PubMed ID: 7829766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.
    Li Q; Rittenhouse PA; Levy AD; Alvarez Sanz MC; Van de Kar LD
    Neuropharmacology; 1992 Oct; 31(10):983-9. PubMed ID: 1359439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Psychobiology of compulsive disease].
    Lesch KP
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):404-12. PubMed ID: 1761269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroendocrine and behavioral responses during conditioned active and passive behavior in the defensive burying/probe avoidance paradigm: effects of ipsapirone.
    Korte SM; Bouws GA; Koolhaas JM; Bohus B
    Physiol Behav; 1992 Aug; 52(2):355-61. PubMed ID: 1355919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.